People with learning disabilities seem to progress faster to severe type 2 diabetes, reveals research

Published On 2025-09-03 03:15 GMT   |   Update On 2025-09-03 08:21 GMT
Advertisement

People with learning disabilities progress faster to severe type 2 diabetes and are at greater risk of dying from their condition than people without these disabilities, suggests research published in the open access journal BMJ Open Diabetes Research & Control.

This is despite having better overall blood glucose control and similar risks of vascular complications, the findings indicate.

Around 1.5 million people (950,000 adults) in the UK have a learning disability, which includes conditions such as Down syndrome and cerebral palsy, note the researchers.

Type 2 diabetes in those with learning disabilities can be challenging as it requires a substantial amount of monitoring and management, which they may not always be able to do, potentially compromising their blood glucose control, explain the researchers.

But there’s been no large study on the potential impact of learning disabilities on the outcomes of type 2 diabetes, including blood glucose control, progression to microvascular and macrovascular complications, initiation of insulin therapy (proxy for severe disease), and risk of death, they add.

Advertisement

Macrovascular complications refer to stroke, coronary heart disease, heart failure, peripheral vascular disease, or amputation more than 6 months after diagnosis of type 2 diabetes. Microvascular complications refer to diabetic nephropathy, retinopathy, or neuropathy.

In a bid to plug this knowledge gap, the researchers extracted anonymised medical records for 352,215 adults newly diagnosed with type 2 diabetes in primary care between January 2004 and January 2021 from the UK Clinical Practice Research Datalink (CPRD) GOLD.

Of these, 280,300 met the eligibility criteria for inclusion in the study, 2074 of whom had a learning disability when they were diagnosed.

They tended to be younger (average age 51 vs 64) and have a shorter monitoring period. And they included higher proportions of men, people of White ethnicity, people living with severe obesity and in areas of greatest deprivation than those without learning disabilities.

They were also more likely to be taking medication for diabetes and high blood pressure and to have more complications related to diabetes at the time of their diagnosis.

Even after adjusting for these potentially influential risk factors they were 19% less likely to have poor blood glucose control than those without learning disabilities 5 years after diagnosis.

But they were 20% more likely to progress faster to severe disease and the need for insulin therapy than those who didn’t have learning disabilities.

And they were around twice as likely to die from any cause and specifically from diabetes despite having similar risks of vascular complications as those who didn’t have learning disabilities.

This is an observational study, and as such, can’t establish cause and effect, and the researchers acknowledge that large numbers of values for the outcome variables for blood glucose control were missing among those with learning disabilities. Complication rates may therefore have either been underdiagnosed or under-recorded, they suggest.

“Our finding of higher rates of insulin initiation in those with learning disabilities warrants further investigation into whether this is due to poorer glycemic control at presentation (and therefore faster advancing type 2 diabetes) or due to having a greater degree of clinical surveillance,” say the researchers.

“Future research into the mechanisms behind this could help reduce health disparities for people with [type 2 diabetes] and learning disabilities,” they add.

Reference:

Wing A, Mathur R. The impact of learning disabilities on control, management, and outcomes of type 2 diabetes mellitus in the UK: an observational cohort study using the Clinical Practice Research Datalink. BMJ Open Diabetes Research & Care. 2025;13:e004879. https://doi.org/10.1136/bmjdrc-2024-004879

Tags:    
Article Source : BMJ Open Diabetes Research & Care

Disclaimer: This website is primarily for healthcare professionals. The content here does not replace medical advice and should not be used as medical, diagnostic, endorsement, treatment, or prescription advice. Medical science evolves rapidly, and we strive to keep our information current. If you find any discrepancies, please contact us at corrections@medicaldialogues.in. Read our Correction Policy here. Nothing here should be used as a substitute for medical advice, diagnosis, or treatment. We do not endorse any healthcare advice that contradicts a physician's guidance. Use of this site is subject to our Terms of Use, Privacy Policy, and Advertisement Policy. For more details, read our Full Disclaimer here.

NOTE: Join us in combating medical misinformation. If you encounter a questionable health, medical, or medical education claim, email us at factcheck@medicaldialogues.in for evaluation.

Our comments section is governed by our Comments Policy . By posting comments at Medical Dialogues you automatically agree with our Comments Policy , Terms And Conditions and Privacy Policy .

Similar News